-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Buy on Rapport Therapeutics, Lowers Price Target to $64

Benzinga·11/06/2026 01:15:21
Listen to the news
UBS analyst Joon Lee maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and lowers the price target from $71 to $64.